Whitehawk Therapeutics (WHWK) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Company overview and strategy

• Launched in early 2025 with a portfolio of three ADC assets in-licensed from WuXi Biologics and led by an experienced team with strong capital backing.

• Two lead ADC assets, HWK-007 (PTK7-directed) and HWK-016 (MUC16-directed), are in clinical trials, with a third (SEZ6-directed, HWK-206) entering the clinic in Q3 2025.

• Cash reserves of $160 million as of Q3 2024 provide runway into 2028, supporting clinical development and data readouts.

Technology platform and differentiation

• ADC platform features high-affinity antibody targeting, attenuated FC regions to reduce off-target toxicity, and innovative bioconjugation for improved stability.

• Utilizes paired chain bioconjugation to maintain antibody integrity and minimize free payload in circulation.

• Employs PEG-masked, Topo 1-based payloads for selective intracellular release, aiming to maximize tumor killing and minimize toxicity.

Preclinical and clinical progress

• ADCs demonstrate 3–10x greater potency, 5–25x higher stability, and 2–3x improved safety margins compared to typical Topo 1 ADCs in preclinical models.

• HWK-007 targets PTK7, a broadly expressed and clinically validated tumor antigen, showing superior potency and safety over prior molecules.

• HWK-016 targets MUC16, highly expressed in gynecological cancers, with an antibody designed to avoid antigen sink and improve tumor targeting.

• HWK-206 (SEZ6-directed) uses a biparotopic antibody for enhanced internalization and aims to outperform existing competitors.